148 related articles for article (PubMed ID: 31821501)
1. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.
Burger EA; de Kok IMCM; Groene E; Killen J; Canfell K; Kulasingam S; Kuntz KM; Matthijsse S; Regan C; Simms KT; Smith MA; Sy S; Alarid-Escudero F; Vaidyanathan V; van Ballegooijen M; Kim JJ
J Natl Cancer Inst; 2020 Sep; 112(9):955-963. PubMed ID: 31821501
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination.
Nartey Y; Hill P; Amo-Antwi K; Asmah R; Nyarko K; Yarney J; Damale N; Cox B
Ghana Med J; 2018 Jun; 52(2):94-102. PubMed ID: 30662082
[TBL] [Abstract][Full Text] [Related]
3. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.
Kim SC; Feldman S; Moscicki AB
Rheumatology (Oxford); 2018 Jul; 57(suppl_5):v26-v33. PubMed ID: 30137592
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Cervical Precancers is the Major Remaining Challenge in Cervical Screening Research.
Desai KT; de Sanjosé S; Schiffman M
Cancer Prev Res (Phila); 2023 Dec; 16(12):649-651. PubMed ID: 38037384
[TBL] [Abstract][Full Text] [Related]
5. Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study.
Pataky RE; Izadi-Najafabadi S; Smith LW; Gottschlich A; Ionescu D; Proctor L; Ogilvie GS; Peacock S
CMAJ; 2024 Jun; 196(21):E716-E723. PubMed ID: 38830680
[TBL] [Abstract][Full Text] [Related]
6. Carcinogenic human papillomavirus infection.
Schiffman M; Doorbar J; Wentzensen N; de Sanjosé S; Fakhry C; Monk BJ; Stanley MA; Franceschi S
Nat Rev Dis Primers; 2016 Dec; 2():16086. PubMed ID: 27905473
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.
Malagón T; Franco EL; Tejada R; Vaccarella S
Nat Rev Clin Oncol; 2024 Jul; 21(7):522-538. PubMed ID: 38760499
[TBL] [Abstract][Full Text] [Related]
8. Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.
Portnoy A; Pedersen K; Kim JJ; Burger EA
Br J Cancer; 2024 Jun; 130(12):1951-1959. PubMed ID: 38643338
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
Broshkevitch CJ; Barnabas RV; Liu G; Palanee-Phillips T; Rao DW
PLoS One; 2024; 19(5):e0301997. PubMed ID: 38781268
[TBL] [Abstract][Full Text] [Related]
10. Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.
Ginindza TG; Sartorius B
BMC Cancer; 2018 Jun; 18(1):639. PubMed ID: 29879943
[TBL] [Abstract][Full Text] [Related]
11. Joint modeling HIV and HPV using a new hybrid agent-based network and compartmental simulation technique.
Zhao X; Gopalappa C
PLoS One; 2023; 18(11):e0288141. PubMed ID: 37922306
[TBL] [Abstract][Full Text] [Related]
12. Questionnaire survey on the prevention and development of cervical cancer in patients with systemic lupus erythematosus in Japan.
Murakawa Y; Dobashi H; Kondo M; Nishiyama S; Okazaki R; Hasegawa Y; Moriyama M; Sugiura T; Onishi I; Honda M; Nagamura N; Yoshioka Y; Minamoto T
Mod Rheumatol; 2024 Feb; 34(2):352-358. PubMed ID: 36929382
[TBL] [Abstract][Full Text] [Related]
13. Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
Bridge F; Brotherton J; Stankovich J; Sanfilippo PG; Skibina OG; Buzzard K; Kalincik T; Nguyen AL; Guo K; Monif M; Wrede CD; Rath L; Taylor L; Butzkueven H; Jokubaitis VG; Van Der Walt A
Neurology; 2024 Feb; 102(4):e208059. PubMed ID: 38306594
[TBL] [Abstract][Full Text] [Related]
14. Mathematical Models for Evaluating Effectiveness and Cost-Effectiveness of Cervical Cancer Control Policies in Populations Including Women Living With Human Immunodeficiency Virus: A Scoping Review.
Iskandar R; Taghavi K; Low N; Bramer WM; Egger M; Rohner E
Value Health Reg Issues; 2022 Nov; 32():39-46. PubMed ID: 36063639
[TBL] [Abstract][Full Text] [Related]
15. Impact of screening on cervical cancer incidence in England: a time trend analysis.
Pesola F; Sasieni P
BMJ Open; 2019 Jan; 9(1):e026292. PubMed ID: 30679300
[TBL] [Abstract][Full Text] [Related]
16. Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment.
Brotherton JML; Wheeler C; Clifford GM; Elfström M; Saville M; Kaldor J; Machalek DA
Prev Med; 2021 Mar; 144():106293. PubMed ID: 33075352
[TBL] [Abstract][Full Text] [Related]
17. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence.
Vaccarella S; Franceschi S; Engholm G; Lönnberg S; Khan S; Bray F
Br J Cancer; 2014 Aug; 111(5):965-9. PubMed ID: 24992581
[TBL] [Abstract][Full Text] [Related]
18. Prospects for accelerated elimination of cervical cancer.
Dillner J; Elfström KM; Baussano I
Prev Med; 2021 Dec; 153():106827. PubMed ID: 34599922
[TBL] [Abstract][Full Text] [Related]
19. A Suggested Approach to Simplify and Improve Cervical Screening in the United States.
Schiffman M; Wentzensen N
J Low Genit Tract Dis; 2016 Jan; 20(1):1-7. PubMed ID: 26704326
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
Sadri Nahand J; Moghoofei M; Salmaninejad A; Bahmanpour Z; Karimzadeh M; Nasiri M; Mirzaei HR; Pourhanifeh MH; Bokharaei-Salim F; Mirzaei H; Hamblin MR
Int J Cancer; 2020 Jan; 146(2):305-320. PubMed ID: 31566705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
